印度新的GST改革削减了对基本药品和胰岛素的税收,降低了成本并改善了获得治疗的机会。 India’s new GST reforms cut taxes on essential medicines and insulin, lowering costs and improving access.

Beeringer Ingelheim 印度欢迎GST理事会最近进行税收改革,降低基本药品和救生药品的费率,并豁免个人医疗保险政策。 Boehringer Ingelheim India welcomes recent GST Council tax reforms that lower rates on essential medicines and life-saving drugs, and exempt individual health insurance policies. 该公司表示,这些变化将降低治疗成本,支持及时诊断,改善患者对长期治疗的坚持。 The company says the changes will reduce treatment costs, support timely diagnosis, and improve patient adherence to long-term therapies. 该公司以糖尿病和心脏病等非传染性疾病为重点,正在调整定价,以反映新的GST费率,并与保健伙伴合作,确保迅速、透明地实施。 Focusing on non-communicable diseases like diabetes and heart conditions, the firm is adjusting its pricing to reflect new GST rates and working with healthcare partners to ensure swift, transparent implementation. 它认为改革是朝向更公平、可持续和创新型保健制度迈出的一步。 It views the reforms as a step toward a more equitable, sustainable, and innovation-friendly healthcare system.